Perspective Therapeutics, Inc. (CATX)
CATX moved a median of -0.35% 30 minutes after news, and 0.00% by the close. How CATX actually reacts to news — the realized, point-in-time move the market made, measured across 322 labeled events over the last three years with zero look-ahead.
CATX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.58% | 32% | 322 |
| 30-min | -0.35% | 41% | 322 |
| 60-min | -0.45% | 43% | 322 |
| to close | 0.00% | 49% | 322 |
| Middle 50% of CATX reactions | -2.30% to +1.44% |
|---|---|
| Median reaction (30-min) | -0.35% |
| Measured reactions | 322 |
Half of all Perspective Therapeutics, Inc. news events land between -2.30% and +1.44% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CATX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 39 | -1.38% | 21% | -1.35% |
| Rating reiterations | 75 | -0.25% | 41% | -1.22% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how CATX ranks against every other measured name →
That’s how CATX usually reacts — get an email when it moves on news →Email me when CATX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CATX's baseline. Nothing else.
Recent CATX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Perspective Therapeutics For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | +11.52% | |
| Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors | Press release | GlobeNewswire | -1.24% | +11.52% | |
| Perspective Therapeutics Announces Acceptance of [212Pb]VMT-a-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium | Press release | GlobeNewswire | -1.48% | +3.80% | |
| Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 | Press release | GlobeNewswire | +0.92% | +2.03% | |
| Form 8-K Perspective Therapeutics For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | -0.36% | |
| Form 8-K Perspective Therapeutics For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +2.85% | +3.92% | |
| Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-a Positive Solid Tumors | Press release | GlobeNewswire | +2.85% | +3.92% | |
| Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 | Press release | GlobeNewswire | +0.72% | +1.44% | |
| Form 8-K Perspective Therapeutics For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.61% | |
| Form 8-K Perspective Therapeutics For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +1.50% | -0.33% | |
| Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -2.00% | -3.00% | |
| Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-a-NET in GEP-NETs | Press release | GlobeNewswire | -0.71% | +2.13% | |
| Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Oral Presentation at the ESMO Congress 2026 | Press release | GlobeNewswire | -0.17% | +0.34% | |
| Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor | Press release | GlobeNewswire | +0.00% | +0.30% | |
| Form 8-K Perspective Therapeutics For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | +3.71% | |
| Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-a-NET in the Meningioma Cohort of a Phase 1/2a Study | Press release | GlobeNewswire | -0.56% | -1.11% | |
| Form 8-K Perspective Therapeutics For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -2.17% | -6.39% | |
| Form 8-K Perspective Therapeutics For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | -2.17% | |
| Form 8-K Perspective Therapeutics For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | +1.27% | |
| Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma | Press release | GlobeNewswire | +0.79% | +1.27% | |
| Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies | Press release | GlobeNewswire | -0.52% | -1.57% | |
| Form 10-Q Perspective Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.82% | -7.14% | |
| Form 8-K Perspective Therapeutics For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -3.82% | -7.14% | |
| Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results | Press release | GlobeNewswire | -3.82% | -7.14% | |
| Form 8-K Perspective Therapeutics For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -2.26% | -8.52% | |
| Perspective Therapeutics to Provide Several Upcoming Corporate Updates | Press release | GlobeNewswire | -0.67% | +0.22% | |
| Form 8-K Perspective Therapeutics For: Apr 18 | SEC filing · Form 8-K | SEC EDGAR | -5.02% | -0.66% | |
| Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | -5.02% | -0.66% | |
| Form DEF 14A Perspective Therapeutics For: Apr 15 | SEC filing · Form DEF | SEC EDGAR | -0.69% | -3.45% | |
| Form DEFA14A Perspective Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | -0.69% | -3.45% | |
| Perspective Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.94% | +3.04% | |
| Form 8-K Perspective Therapeutics For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | +3.04% | |
| Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the AACR Annual Meeting 2026 | Press release | GlobeNewswire | -0.32% | -2.99% | |
| Form 10-K Perspective Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.58% | -4.44% | |
| Form 8-K Perspective Therapeutics For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -0.58% | -4.44% | |
| Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results | Press release | GlobeNewswire | -0.58% | -4.44% | |
| New Treatment Modalities Are Reaching Cancers That Resisted Everything Else | Press release | PR Newswire | +0.31% | +0.41% | |
| Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results | Press release | GlobeNewswire | -0.95% | +2.97% | |
| Form 8-K Perspective Therapeutics For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | -2.89% | -1.73% | |
| Form 8-K Perspective Therapeutics For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | -3.13% | +21.64% | |
| Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -3.13% | +21.64% | |
| Form 8-K Perspective Therapeutics For: Jan 14 | SEC filing · Form 8-K | SEC EDGAR | -0.78% | +2.75% | |
| Form 8-K Perspective Therapeutics For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -5.04% | -16.32% | |
| Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -5.04% | -16.32% | |
| Form 8-K Perspective Therapeutics For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -1.42% | +1.07% | |
| Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium | Press release | GlobeNewswire | -1.42% | +1.07% | |
| Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.53% | +2.30% | |
| Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium | Press release | GlobeNewswire | +1.35% | +7.66% | |
| Form 8-K Perspective Therapeutics For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | +0.46% | -5.96% | |
| Perspective Therapeutics to Participate in Upcoming December Conferences | Press release | GlobeNewswire | +0.85% | -9.79% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CATX section they belong to.
Where else CATX is measured.
CATX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Perspective Therapeutics, Inc.'s median reaction calculated?
Every labeled CATX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 322 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of CATX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CATX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.